Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
- PMID: 8892868
- PMCID: PMC190817
- DOI: 10.1128/JVI.70.11.7498-7509.1996
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
Abstract
Development of adenovirus vectors as potential therapeutic agents for multiple applications of in vivo human gene therapy has resulted in numerous preclinical and clinical studies. However, lack of standardization of the methods for quantifying the physical concentration and functionally active fraction of virions in these studies has often made comparison between various studies difficult or impossible. This study was therefore carried out to define the variables for quantification of the concentration of adenovirus vectors. The methods for evaluation of total virion concentration included electron microscopy and optical absorbance. The methods for evaluation of the concentration of functional virions included detection of gene transfer (transgene transfer and expression) and the plaque assay on 293 cells. Enumeration of total virion concentration by optical absorbance was found to be a precise procedure, but accuracy was dependent on physical disruption of the virion to eliminate artifacts from light scattering and also on a correct value for the extinction coefficient. Both biological assays for enumerating functional virions were highly dependent on the assay conditions and in particular the time of virion adsorption and adsorption volume. Under optimal conditions, the bioactivity of the vector, defined as the fraction of total virions which leads to detected target cell infection, was determined to be 0.10 in the plaque assay and 0.29 in the gene transfer assay. This difference is most likely due to the fact that detection by gene transfer requires only measurement of levels of transgene expression in the infected cell whereas plaque formation is dependent on a series of biological events of much greater complexity. These results show that the exact conditions for determination of infectious virion concentration and bioactivity of recombinant adenovirus vectors are critical and must be standardized for comparability. These observations may be very useful in comparison of data from different preclinical and clinical studies and may also have important implications for how adenovirus vectors can optimally be used in human gene therapy.
Similar articles
-
Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation.Gene Ther. 1999 May;6(5):873-81. doi: 10.1038/sj.gt.3300897. Gene Ther. 1999. PMID: 10505113
-
Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy.Hum Gene Ther. 1995 Jan;6(1):41-53. doi: 10.1089/hum.1995.6.1-41. Hum Gene Ther. 1995. PMID: 7703286
-
Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors.Gene Ther. 2004 Mar;11(6):504-11. doi: 10.1038/sj.gt.3302107. Gene Ther. 2004. PMID: 14999222
-
Adenovirus vectors and subviral particles for protein and peptide delivery.Curr Gene Ther. 2012 Oct;12(5):362-73. doi: 10.2174/156652312802762563. Curr Gene Ther. 2012. PMID: 22845888 Review.
-
Adenovirus-mediated in vivo gene transfer.Ann N Y Acad Sci. 1994 May 31;716:90-101; discussion 101-3. doi: 10.1111/j.1749-6632.1994.tb21705.x. Ann N Y Acad Sci. 1994. PMID: 7517653 Review.
Cited by
-
Clinical Application of Adenovirus (AdV): A Comprehensive Review.Viruses. 2024 Jul 8;16(7):1094. doi: 10.3390/v16071094. Viruses. 2024. PMID: 39066256 Free PMC article. Review.
-
Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development.Front Immunol. 2024 Feb 12;15:1356600. doi: 10.3389/fimmu.2024.1356600. eCollection 2024. Front Immunol. 2024. PMID: 38410513 Free PMC article.
-
A Method to Generate and Rescue Recombinant Adenovirus Devoid of Replication-Competent Particles in Animal-Origin-Free Culture Medium.Viruses. 2023 Oct 25;15(11):2152. doi: 10.3390/v15112152. Viruses. 2023. PMID: 38005830 Free PMC article.
-
Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8.Cell. 2023 Oct 26;186(22):4818-4833.e25. doi: 10.1016/j.cell.2023.09.007. Epub 2023 Oct 6. Cell. 2023. PMID: 37804831
-
Apolipoprotein A-I vascular gene therapy reduces vein-graft atherosclerosis.Mol Ther Methods Clin Dev. 2023 Aug 22;30:558-572. doi: 10.1016/j.omtm.2023.08.018. eCollection 2023 Sep 14. Mol Ther Methods Clin Dev. 2023. PMID: 37693942 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources